In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Q: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Comprehensive Immunosuppressive Drug 
Coverage for Kidney Transplant Patients Act of 2011''.

SEC. 2. EXTENDED MONTHS OF COVERAGE OF IMMUNOSUPPRESSIVE DRUGS FOR 
              KIDNEY TRANSPLANT PATIENTS AND OTHER RENAL DIALYSIS 
              PROVISIONS.

    (a) Medicare Entitlement to Immunosuppressive Drugs for Kidney 
Transplant Recipients.--
            (1) Kidney transplant recipients.--Section 226A(b)(2) of 
        the Social Security Act (42 U.S.C. 426-1(b)(2)) is amended by 
        inserting ``(except for eligibility for enrollment under part B 
        solely for purposes of coverage of immunosuppressive drugs 
        described in section 1861(s)(2)(J))'' before ``, with the 
        thirty-sixth month''.
            (2) Individuals eligible only for coverage of 
        immunosuppressive drugs.--
                    (A) Section 1836 of the Social Security Act (42 
                U.S.C. 1395o) is amended--
                            (i) by striking ``Every'' and inserting 
                        ``(a) In General.--Every''; and
                            (ii) by inserting at the end the following 
                        new subsection:
    ``(b) Individuals Eligible for Immunosuppressive Drug Coverage.--
Beginning on January 1, 2012, every individual whose insurance benefits 
under part A have ended (whether before, on, or after such date) by 
reason of section 226A(b)(2) is eligible for enrollment in the 
insurance program established by this part solely for purposes of 
coverage of immunosuppressive drugs.''.
                    (B) Conforming amendment.--Sections 1837, 1838, and 
                1839 of the Social Security Act (42 U.S.C. 1395(p), 42 
                U.S.C. 1395(q), 42 U.S.C. 1395(r)) are each amended by 
                striking ``1836'' and inserting ``1836(a)'' each place 
                it appears.
            (3) Enrollment for individuals only eligible for coverage 
        of immunosuppressive drugs.--Section 1837 of the Social 
        Security Act (42 U.S.C. 1395(p)) is amended by adding at the 
        end the following new subsection:
    ``(m)(1) Any individual who is eligible under section 1836(b) to 
enroll in the medical insurance program established under this part for 
purposes of coverage of immunosuppressive drugs may enroll only in such 
manner and form as may be prescribed by regulations, and only during an 
enrollment period described in this subsection.
    ``(2) An individual described in paragraph (1) may enroll beginning 
on the first day of the third month before the month in which the 
individual first satisfies section 1836(b).
    ``(3) An individual described in paragraph (1) whose entitlement 
for hospital insurance benefits under part A ends by reason of section 
226A(b)(2) on or after January 1, 2012, shall be deemed to have 
enrolled in the medical insurance program established by this part for 
purposes of coverage of immunosuppressive drugs.''.
            (4) Coverage period for individuals only eligible for 
        coverage of immunosuppressive drugs.--
                    (A) In general.--Section 1838 of the Social 
                Security Act (42 U.S.C. 1395q) is amended by adding at 
                the end the following new subsection:
    ``(g) In the case of an individual described in section 1836(b), 
the following rules shall apply:
            ``(1) In the case of such an individual who is deemed to 
        have enrolled in part B for coverage of immunosuppressive drugs 
        under section 1837(m)(3), such individual's coverage period 
        shall begin on the first day of the month in which the 
        individual first satisfies section 1836(b).
            ``(2) In the case of such an individual who enrolls in part 
        B for coverage of immunosuppressive drugs under section 
        1837(m)(2), such individual's coverage period shall begin on 
        the first day of the month in which the individual first 
        satisfies section 1836(b) or the month following the month in 
        which the individual so enrolls, whichever is later.
            ``(3) The provisions of subsections (b) and (d) shall apply 
        with respect to an individual described in paragraph (1) or 
        (2).
            ``(4) In addition to the reasons for termination under 
        subsection (b), the coverage period of an individual described 
        in paragraph (1) or (2) shall end when the individual becomes 
        entitled to benefits under this title under section 226(a), 
        226(b), or 226A.''.
                    (B) Conforming amendments.--Section 1838(b) of the 
                Social Security Act (42 U.S.C. 1395q(b)) is amended, in 
                the matter following paragraph (2), by adding ``or 
                section 1837(m)(3)'' after ``section 1837(f)'' each 
                place it appears.
            (5) Premiums for individuals only eligible for coverage of 
        immunosuppressive drugs.--Section 1839 of the Social Security 
        Act (42 U.S.C. 1395r) is amended--
                    (A) in subsection (b), by adding at the end the 
                following new sentence: ``No increase in the premium 
                shall be effected for individuals who are enrolled 
                pursuant to section 1836(b) for coverage only of 
                immunosuppressive drugs.''; and
                    (B) by adding at the end the following new 
                subsection:
    ``(j) Determination of Premium for Individuals Only Eligible for 
Coverage of Immunosuppressive Drugs.--The Secretary shall, during 
September of each year, determine and promulgate a monthly premium rate 
for the succeeding calendar year for individuals who enroll only for 
the purpose of coverage of immunosuppressive drugs under section 
1836(b). Such premium shall be equal to 35 percent of the monthly 
actuarial rate for enrollees age 65 and over, determined according to 
paragraph (1), for that succeeding calendar year. The monthly premium 
of each individual enrolled for coverage of immunosuppressive drugs 
under section 1836(b) for each month shall be the amount promulgated in 
this subsection. Such amount shall be adjusted in accordance with 
subsections (c) and (f).''.
            (6) Government contribution.--Section 1844(a) of the Social 
        Security Act (42 U.S.C. 1395w(a)) is amended--
                    (A) in paragraph (3), by striking the period at the 
                end and inserting ``; plus'';
                    (B) by adding at the end the following new 
                paragraph:
            ``(4) a Government contribution equal to the estimated 
        aggregate reduction in premiums payable under part B that 
        results from establishing the premium at 35 percent of the 
        actuarial rate under section 1839(j) instead of 50 percent of 
        the actuarial rate for individuals who enroll only for the 
        purpose of coverage of immunosuppressive drugs under section 
        1836(b).''; and
                    (C) by adding at the end the following flush 
                matter:
        ``The Government contribution under paragraph (4) shall be 
        treated as premiums payable and deposited for purposes of 
        subparagraphs (A) and (B) of paragraph (1).''.
            (7) Extension of secondary payer requirements for esrd 
        beneficiaries eligible for coverage of immunosuppressive 
        drugs.--Section 1862(b)(1)(C) of the Social Security Act (42 
        U.S.C. 1395(y)(b)(1)) is amended by adding at the end the 
        following new sentence: ``With regard to immunosuppressive 
        drugs furnished to an individual who enrolls for the purpose of 
        coverage of immunosuppressive drugs under section 1836(b) on or 
        after January 1, 2012, this subparagraph shall apply without 
        regard to any time limitation, except that when such individual 
        becomes entitled to benefits under this title under sections 
        226(a) or 226(b), or entitled to or eligible for benefits under 
        this title under section 226A, the provisions of subparagraphs 
        (A) and (B), and the time limitations under this subparagraph, 
        respectively, shall apply.''.
            (8) Ensuring coverage under the medicare savings program.--
        Section 1905(p)(1)(A) of the Social Security Act (42 U.S.C. 
        1396d(p)(1)(A)) is amended by inserting ``or an individual who 
        is enrolled under part B for the purpose of coverage of 
        immunosuppressive drugs under section 1836(b)'' after ``section 
        1818''.
            (9) Part d.--Section 1860D-1(a)(3)(A) of the Social 
        Security Act (42 U.S.C. 1395w-101(a)(3)(A)) is amended by 
        inserting ``(but not including an individual enrolled solely 
        for coverage of immunosuppressive drugs under section 
        1836(b))'' before the period at the end.

A: Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011 - Amends title II (Old Age, Survivors and Disability Benefits) (OASDI) of the Social Security Act (SSA) to extend the months of coverage of immunosuppressive drugs for kidney transplant patients.

Amends SSA title XVIII (Medicare) to make eligible for enrollment in Medicare part B (Supplementary Medical Insurance), solely for the purpose of such drug coverage, every individual whose insurance benefits under Medicare part A (Hospital Insurance) have ended by reason of a kidney transplant or the end of any requirement for a regular course of dialysis.

Directs the Secretary of Health and Human Services (HHS) to determine a monthly premium rate for such individuals equal to 35% of the monthly actuarial rate for enrollees age 65 and over. Prescribes a formula for detemination of a government contribution to such a premium.
****
Q: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Financial Information Privacy Act of 
1999''.

SEC. 2. DEFINITIONS.

    In this Act--
            (1) the term ``covered person'' means a person that is 
        subject to the jurisdiction of any of the Federal financial 
        regulatory authorities; and
            (2) the term ``Federal financial regulatory authorities'' 
        means--
                    (A) each of the Federal banking agencies, as that 
                term is defined in section 3(z) of the Federal Deposit 
                Insurance Act; and
                    (B) the Securities and Exchange Commission.

SEC. 3. PRIVACY OF CONFIDENTIAL CUSTOMER INFORMATION.

    (a) Rulemaking.--The Federal financial regulatory authorities shall 
jointly issue final rules to protect the privacy of confidential 
customer information relating to the customers of covered persons, not 
later than 270 days after the date of enactment of this Act (and shall 
issue a notice of proposed rulemaking not later than 150 days after the 
date of enactment of this Act), which rules shall--
            (1) define the term ``confidential customer information'' 
        to be personally identifiable data that includes transactions, 
        balances, maturity dates, payouts, and payout dates, of--
                    (A) deposit and trust accounts;
                    (B) certificates of deposit;
                    (C) securities holdings; and
                    (D) insurance policies;
            (2) require that a covered person may not disclose or share 
        any confidential customer information to or with any affiliate 
        or agent of that covered person if the customer to whom the 
        information relates has provided written notice, as described 
        in paragraphs (4) and (5), to the covered person prohibiting 
        such disclosure or sharing--
                    (A) with respect to an individual that became a 
                customer on or after the effective date of such rules, 
                at the time at which the business relationship between 
                the customer and the covered person is initiated and at 
                least annually thereafter; and
                    (B) with respect to an individual that was a 
                customer before the effective date of such rules, at 
                such time thereafter that provides a reasonable and 
                informed opportunity to the customer to prohibit such 
                disclosure or sharing and at least annually thereafter;
            (3) require that a covered person may not disclose or share 
        any confidential customer information to or with any person 
        that is not an affiliate or agent of that covered person unless 
        the covered person has first--
                    (A) given written notice to the customer to whom 
                the information relates, as described in paragraphs (4) 
                and (5); and
                    (B) obtained the informed written or electronic 
                consent of that customer for such disclosures or 
                sharing;
            (4) require that the covered person provide notices and 
        consent acknowledgments to customers, as required by this 
        section, in separate and easily identifiable and 
        distinguishable form;
            (5) require that the covered person provide notice as 
        required by this section to the customer to whom the 
        information relates that describes what specific types of 
        information would be disclosed or shared, and under what 
        general circumstances, to what specific types of businesses or 
        persons, and for what specific types of purposes such 
        information could be disclosed or shared;
            (6) require that the customer to whom the information 
        relates be provided with access to the confidential customer 
        information that could be disclosed or shared so that the 
        information may be reviewed for accuracy and corrected or 
        supplemented;
            (7) require that, before a covered person may use any 
        confidential customer information provided by a third party 
        that engages, directly or indirectly, in activities that are 
        financial in nature, as determined by the Federal financial 
        regulatory authorities, the covered person shall take 
        reasonable steps to assure that procedures that are 
        substantially similar to those described in paragraphs (2) 
        through (6) have been followed by the provider of the 
        information (or an affiliate or agent of that provider); and
            (8) establish a means of examination for compliance and 
        enforcement of such rules and resolving consumer complaints.
    (b) Limitation.--The rules prescribed pursuant to subsection (a) 
may not prohibit the release of confidential customer information--
            (1) that is essential to processing a specific financial 
        transaction that the customer to whom the information relates 
        has authorized;
            (2) to a governmental, regulatory, or self-regulatory 
        authority having jurisdiction over the covered financial entity 
        for examination, compliance, or other authorized purposes;
            (3) to a court of competent jurisdiction;
            (4) to a consumer reporting agency, as defined in section 
        603 of the Fair Credit Reporting Act for inclusion in a 
        consumer report that may be released to a third party only for 
        a purpose permissible under section 604 of that Act; or
            (5) that is not personally identifiable.
    (c) Construction.--Nothing in this section or the rules prescribed 
under this section shall be construed to amend or alter any provision 
of the Fair Credit Reporting Act.

A: Financial Information Privacy Act of 1999 - Directs the Federal financial regulatory authorities (banking regulatory agencies and the Securities and Exchange Commission (SEC)) to jointly issue final rules to protect the privacy of confidential information relating to customers of institutions under their respective jurisdictions (covered institution). 
Mandates that such rules: (1) prohibit a covered institution from disclosing or sharing confidential customer information with any affiliate or agent if the customer has provided a written notice which forbids such disclosure; (2) prohibit a covered institution from disclosing or sharing confidential customer information with a non-affiliate or non-agent unless the customer has provided written or electronic consent; (3) require the covered institution to disclose to the customer the specific type of information disclosed or shared, under what circumstances, to what specific types of businesses, and for what types of purposes; (4) require customer access to information that could be disclosed so that it may be reviewed for accuracy and supplementation; and (5) establish a compliance and enforcement mechanism that includes consumer complaint resolution. 
Cites circumstances under which such information may be released.
****
Q: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Russian Fissile Materials 
Disposition Loan Guarantee Act of 2001''.

SEC. 2. FINDINGS.

    Congress makes the following findings:
            (1) The proliferation of nuclear weapons represents a risk 
        to the national security of the United States.
            (2) Countries seeking new nuclear weapons capabilities 
        require both technical expertise and nuclear weapons materials.
            (3) The nuclear weapons complex of the former Soviet Union 
        contains large amounts of such technical expertise and 
        materials and could present risks for nuclear proliferation.
            (4) Several current programs address the potential for loss 
        of such technical expertise and materials.
            (5) Progress on the Highly Enriched Uranium Agreement and 
        on the Plutonium Disposition Agreement will enhance United 
        States security against nuclear proliferation, but United 
        States security would be further enhanced were additional 
        progress achieved in securing and disposing of the nuclear 
        weapons materials of the former Soviet Union.
            (6) In addition to the programs referred to in paragraphs 
        (4) and (5), a program providing for the placement of nuclear 
        weapons materials of the Russian Federation under permanent 
        safeguards in exchange for the guarantee of loans for 
        nonproliferation programs and activities of the Russian 
        Federation could enhance the economy of the Russian Federation 
        and achieve the interest of nations worldwide in providing for 
        the security of nuclear weapons materials that are not 
        currently under international safeguards.

SEC. 3. LOAN GUARANTEES.

    (a) Authority To Guarantee Loan.--Subject to the provisions of this 
section, the Secretary of Energy may, with the approval of the 
President, guarantee loans made to the Government of the Russian 
Federation for purposes described in subsection (c)(1).
    (b) Limitations on Guarantees.--(1) The aggregate amount of loan 
principal covered by guarantees under this section at any one time may 
not exceed $1,000,000,000.
    (2) The guarantee of a loan under this section applies to principal 
and to interest specified in the loan, except that the guarantee on 
interest shall not apply to amounts allocable to interest at a rate in 
excess of 3 percent per year.
    (c) Loans Eligible for Guarantee.--(1) A loan eligible for 
guarantee under this section is any loan made by a private lender to 
the Government of the Russian Federation the proceeds of which are to 
be utilized by the Government of the Russian Federation for one or more 
of the following purposes:
            (A) Retirement of the sovereign debt of the Russian 
        Federation.
            (B) Support of nuclear nonproliferation programs and 
        activities of the Government of the Russian Federation.
            (C) Development of the energy infrastructure of the Russian 
        Federation, including peaceful uses of nuclear energy in a 
        manner that complies with the Nuclear Nonproliferation Treaty.
    (2) A loan is not eligible for guarantee under this section if the 
proceeds of the loan are to be used for any purpose or activity under 
the Plutonium Disposition Agreement, including to cover the costs of 
the manufacture and use of mixed oxide (MOX) fuel in Russia under the 
Plutonium Disposition Agreement.
    (d) Loan Terms.--A loan guaranteed under this section shall have 
the following terms:
            (1) The loan principal shall be in increments of 
        $20,000,000.
            (2) The term of the loan with respect to any principal 
        increment of the loan shall be not less than 15 years.
            (3) Payments of principal and interest on the loan shall be 
        based on an amortization schedule providing that--
                    (A) interest on a principal increment of the loan 
                will commence on the date of the disbursement of the 
                principal increment of the loan;
                    (B) no payment of principal or interest on a 
                principal increment of the loan will be required for at 
                least 5 years after the date of the disbursement of the 
                principal increment of the loan;
                    (C) once payments of principal and interest 
                commence pursuant to subparagraph (B), such payments 
                will be made on a semi-annual basis; and
                    (D) all interest and principal on each principal 
                increment of the loan will be due and payable not later 
                than the completion of the term of the loan with 
                respect to such principal increment of the loan.
            (4) The proceeds of the loan shall be disbursed to the 
        Russian Federation or a department or ministry of the Russian 
        Federation.
            (5) The lender may, upon default of the Government of the 
        Russian Federation on the loan, exercise the option described 
        in subsection (e)(3).
    (e) Loan Security.--(1) As security for a loan guaranteed under 
this section, the Government of the Russian Federation shall, for each 
loan principal increment of $20,000,000, place 1.00 metric tons of 
weapons-usable plutonium and 1.00 metric tons of weapons-usable highly 
enriched uranium under International Atomic Energy Agency (IAEA) 
safeguards at a facility in Russia that is mutually acceptable to 
Russia and the IAEA. The placement of materials under such safeguards 
as security for a principal increment of a loan shall be completed 
before the disbursement of the principal increment of the loan.
    (2) As security for a loan guaranteed under this section, the 
Government of the Russian Federation shall certify to the Secretary 
that any materials placed under International Atomic Energy Agency 
safeguards pursuant to paragraph (1) shall remain under such safeguards 
indefinitely, including after the loan is paid off by the Government of 
the Russian Federation.
    (3)(A) In the event of a default on a loan guaranteed under this 
section by the Government of the Russian Federation, the lender may, 
with the approval of the Secretary, provide for the disposition or 
utilization of materials placed under safeguards pursuant to paragraph 
(1) as security for the loan to repay all or part of the loan.
    (B) The disposition or utilization of materials under this 
paragraph shall be in accordance with applicable International Atomic 
Energy Agency safeguards regarding such materials, and such materials 
may not, during the course of such disposition or utilization, be 
removed from such safeguards.
    (4) Materials placed under International Atomic Energy Agency 
safeguards pursuant to paragraph (1) shall not be treated as part of 
the 34.00 metric tons of weapons-grade plutonium to be used by the 
Government of the Russian Federation largely as mixed oxide (MOX) fuel 
under the Plutonium Disposition Agreement.
    (f) Treatment of Guarantees Under Plutonium Disposition 
Agreement.--The guarantee of any loan under this section shall not be 
treated as a contribution to the Government of the Russian Federation 
under the Plutonium Disposition Agreement.
    (g) Prohibition on Collection of Fees.--The Secretary may not 
impose or collect any fee in connection with the guarantee of a loan 
under this section.

SEC. 4. SUPPORT OF INTERNATIONAL ATOMIC ENERGY AGENCY MATERIALS 
              SAFEGUARDS.

    Of the amounts authorized to be appropriated or otherwise made 
available to the Secretary of Energy each fiscal year for Materials 
Protection Control and Accounting, not more than $15,000,000 shall be 
available to the Secretary for purposes of covering the expenses of the 
International Atomic Energy Agency (IAEA) in implementing and 
maintaining safeguards under section 3(e) on materials providing 
security for loans guaranteed under section 3.

SEC. 5. AUTHORIZATION OF APPROPRIATIONS.

    (a) Cost of Loan Guarantees.--For the cost of the loans guaranteed 
under this Act as defined in section 502 of the Congressional Budget 
Act of 1974 (2 U.S.C. 661(a)), there is authorized to be appropriated 
for fiscal years 2002 through 2005, such amounts as may be necessary.
    (b) Cost of Administration.--There is hereby authorized to be 
appropriated to the Secretary of Energy for fiscal year 2002, 
$10,000,000 for purposes of activities under this Act, other than to 
cover costs under subsection (a) and to cover expenses under section 4.
    (c) Availability.--Amounts appropriated pursuant to the 
authorizations of appropriations in subsections (a) and (b) shall 
remain available until expended.

SEC. 6. DEFINITIONS.

    In this Act:
            (1) Highly enriched uranium agreement.--The term ``Highly 
        Enriched Uranium Agreement'' means the Agreement Between the 
        United States of America and the Government of the Russian 
        Federation Concerning the Disposition of Highly Enriched 
        Uranium Extracted from Nuclear Weapons, dated February 18, 
        1993.
            (2) Nuclear nonproliferation treaty.--The term ``Nuclear 
        Nonproliferation Treaty'' means the Treaty on the 
        Nonproliferation of Nuclear Weapons, as opened for signature 
        July 1, 1968.
            (3) Plutonium disposition agreement.--The term ``Plutonium 
        Disposition Agreement'' means the Agreement Between the 
        Government of the United States of America and the Government 
        of the Russian Federation Concerning the Management and 
        Disposition of Plutonium Designated As No Longer Required for 
        Defense Purposes and Related Cooperation, signed by the United 
        States on September 1, 2000.

SEC. 7. TERMINATION OF AUTHORITY.

    The authority of the Secretary of Energy to guarantee loans under 
this Act shall terminate on December 31, 2004. The termination of 
authority to guarantee loans under this section shall not affect the 
validity of any guarantee made under this Act before that date.

A:
Russian Fissile Materials Disposition Loan Guarantee Act of 2001 - Authorizes the Secretary of Energy, with the President's approval, to guarantee loans (principal and up to three percent per year on interest) made to the Government of the Russian Federation (GRF) for: (1) retirement of the sovereign debt of the Russian Federation; and (2) nuclear nonproliferation programs and activities. Sets forth certain guaranteed loan requirements.
****